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Aims: To measure levels of intermedin and calcitonin gene-related peptide (CGRP) in acute coronary syndrome
(ACS) and to determine if they are elevated.
Methods and results: 81 patients admitted with suspected ACS were enrolled into the study. 50 were conﬁrmed
ACS by ACC (2000) guidelines and 31 were in a control group as non-cardiac chest pain. Intermedin was non-
signiﬁcantly elevated 6.14 pg/ml vs 4.84 pg/ml b8 h in the ACS group; sensitivity 68%, speciﬁcity 63% on
presenting sample. Intermedinwas signiﬁcantly elevated in those patientswhohad an initially negative troponin
T (b0.03 ng/ml) on presentation, 6.67 pg/ml vs 4.84 pg/ml, p = 0.03.
CGRP was signiﬁcantly elevated in ACS patients, 8–b16 h after pain onset, 8.67 pg/ml vs 7.08 pg/ml, p = 0.036.
However, it didn't aid diagnosis in initially negative troponin patients; sensitivity 61%, speciﬁcity 60% on
presenting sample. Both intermedin and CGRP were elevated in STEMI patients on a ﬁrst sample, but only inter-
medin was signiﬁcantly elevated; 7.03 pg/ml vs 4.84 pg/ml, p = 0.02 and 8.87 pg/ml vs 7.03 pg/ml p = 0.093,
respectively.
High sensitivity troponin T was signiﬁcant elevated in the ACS group at b8 h (414.9 vs 17.22, p = 0.006) and at
8–b16 h (3325.27 vs 21.54, p = 0.02).
Conclusions: Both intermedin andCGRP are detectable inhumanpatients. Levels show a trend to elevation inACS,
with CGRP being signiﬁcantly raised N8 h after pain onset. The degree of elevation will have limited clinical
applicability.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Chest pain remains a common presenting complaint to the
Emergency Department, but only 15% of chest pain attendees actually
have an ischaemic origin to their pain [1]. Separating acute coronary
syndrome (ACS) from non-ischaemic chest pain or unstable angina
can be performed by measurement of biomarkers of cardiac injury.
Thygesen's redeﬁnition of acute myocardial infarction [2] deﬁned the
diagnosis of myocardial infarction as a rise and fall of troponin greater
than the 99th percentile in a normal population. This was applicable
as long as the assay used, had acceptable precision at this level, clinically
deﬁned as a coefﬁcient of variation less than 10% [3]. The recently intro-
duced highly sensitive troponin assays meet these criteria [4–6].ast Health and Social Care Trust,
el 9, Belfast City Hospital, Belfast
AB, United Kingdom. Tel.: +44
ce).
d Ltd. This is an open access article unThe enhanced clinical sensitivity of the highly sensitive troponins is
accompanied by a reduced speciﬁcity for diagnosing myocardial infarc-
tion compared to the standard troponin assays. The highly sensitive
troponin can be raised in conditions other than ACS [7]. A delta change
in the high sensitivity troponin T level necessitating a second sample
after a few hours is therefore required. This means further blood
sampling and prolonging the patient's period of uncertain diagnosis.
Anothermeans of determining an ischaemic basis to the rise in troponin
is to use another marker with the troponin. This study assesses two
new markers, intermedin and calcitonin gene-related peptide, in the
diagnosis of acute coronary syndrome.
The calcitonin gene-related peptide family is a group of peptides that
includes calcitonin gene-related peptide (CGRP), adrenomedullin,
amylin and intermedin [8].
Intermedin or adrenomedullin 2 was discovered simultaneously by
two different research groups [8,9]. It is a 47 amino acid peptide
which has some similarities to CGRP. Whilst initially found in the
pituitary (from the intermediate lobe of the anterior pituitary, hence
its name) it is also found in animal models in the kidney, brain, GI
tract skin, pancreas, lung, spleen, thymus and ovary [10]. At human
autopsy intermedin has been localised to cardiomyocytes and in lesserder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Fig. 1. Patient ﬂow in the study.
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[11].We have shown in our unit that intermedin protects human vascu-
lar and cardiac non-vascular cells from oxidative stress and ischaemic
reperfusion injury [12]. Infusion of intermedin at time of myocardial
infarction in rat hearts did appear to attenuate the ischaemia reperfu-
sion injury [13].
CGRP is a 37 amino acid peptide that is found throughout the central
and peripheral nervous system, most commonly in nerves that are
associated with blood vessels. It's release into the blood stream causes
mainly local vasodilatation [14]. In the heart where there is a high con-
centration of CGRP nerve ﬁbres [15] there is immunoreactive evidence
of an increase in CGRP levels following infarction and at nerve endings
[16].When the LADwas occluded in dogs, with subsequent reperfusion,
CGRP improved the contractile function [17]. Kallner found raised levels
of CGRP in pig hearts 10–20 min after onset of myocardial ischaemia in
coronary sinus sampling. However when exogenous CGRP was admin-
istered following an infarct, it precipitated hypotension, and failed to
reduce the size of the infarct [18].
No data exists for these markers in human myocardial ischaemia/
infarction.
2. Aims and objectives
The study aimed to document levels of intermedin and CGRP in
patients with chest pain and determine if plasma levels are increased
in acute coronary syndrome.
3. Methods
Subjects were enrolled into the study over a 15-month period from
February 2008. The study conformed to the declaration of Helsinki and
all patients gave informed written consent to enter the study, with the
study protocol having been approved by the NHS research ethics
committee for Northern Ireland. Patients were recruited on weekdays
from those admitted to the Belfast City Hospital with chest pain of a
suspected ischaemic nature.
All subjects were eligible for inclusion, the only exclusion being
an age less than 18 years or an inability to consent. Subjects received
a standard evaluation, including history, physical examination and
12-lead ECG. These details were recorded along with, cardiovascular
risk factors, haematological and biochemical results and blood sample
timing from chest pain onset.
3.1. Sampling
Blood was sampled on admission and then at 12 h after the chest
pain onset along with a standard care troponin T (Roche — cut-off
b0.03 ng/ml, 10% CV). Those patients diagnosed as a myocardial infarc-
tion, by independent clinicians using the 2000 ACC guidelines, had
further samples taken on day 2 and day 3 of their admission.Myocardial
infarction patients presenting after 12 h still had the later samples
taken. Twenty millilitres of blood was taken at each time point. The
blood was collected in EDTA tubes with the addition of aprotinin
(780 KIU ml−1) to prevent peptide breakdown. The samples were
collected on ice and centrifuged at 3500 rpm for 15 min, with the
plasma being separated and stored in a−80 °C freezer until peptide
analysis.
3.2. Assays
The peptides were solidiﬁed from the plasma using a solid phase
extraction technique with the serum loaded onto washed Sep-Pak C18
cartridges (Waters SepPak©). The columns were washed with a buffer
of triﬂuoroacetic acid, and then collected in a buffer of acetonitrile.
This eluant was evaporated to 40% dryness by spinning in a centrifugalconcentrator (Hetero Vac VR-1) and ﬁnally, freeze dried using a lyoph-
ilizer (Modulyo Freeze Dryer).
Peptide values were obtained using a radioimmunoassay kit
(Phoenix Pharmaceuticals). The sampleswere incubatedwith a primary
antibody and then radioactive iodine. The primary antibody was rabbit
anti-peptide serum and was speciﬁc for the three active forms of inter-
medin or two active forms of CGRP, as shown in Appendix A. The bound
sample was then precipitated out with the use of a secondary antibody
and the radioactive count measured using a gamma counter. Using
known standards, a binding curve could then be generated which
allowed the amount of peptide to be derived. They were analysed in
batches of 49 in duplicate samples [19].
The coefﬁcient of variation in our laboratory for CGRPwas 9.72% and
for intermedin 2.8%.
This method was used to measure intermedin and calcitonin gene-
related peptide, all other biochemical results were carried out by the
CPA (Clinical Pathology Accreditation UK) hospital laboratory.
Statistical analysis was performed using SPSS version 19, with values
given as mean ± SD. Differences were assessed using the student's
t-test, chi-squared test or Fisher's exact test as appropriate. Signiﬁcance
was at the 5% level and was a two-sided analysis.4. Results
The patients were divided into two groups depending on their
diagnosis (ACS or non-cardiac chest pain), which was decided by an
Table 1
Table demonstrating baseline characteristics of both groups.
Baseline characteristics. ACE, angiotension converting enzyme inhibitor; ARB, angiotension II receptor blockers.
ACS Non-cardiac chest pain Signiﬁcance at 5%
N = 81 50 31
Age. Mean (SD)
Range
66.72 (14.5)
36–89
60.26 (13.4)
40–84
p = 0.048
Sex n (%)
Male 34 (68%) 20 (65%) p = 0.746
Female 16 (32%) 11 (35%)
Hypertension 20 (40%) 20 (65%) p = 0.032
Diabetes 9 (18%) 3 (10%) p = 0.356
Smoker 21 (42%) 14 (45%) p = 0.78
Hypercholesterolaemia 26 (52%) 15 (48%) p = 0.752
Family history of cardiac disease 31 (62%) 19 (61%) p = 0.95
Past history of ischaemic heart disease 18 (36%) 16 (52%) p = 0.166
Haemoglobin g/dl 13.51 (2.09) 13.73 (2.08) p = 0.65
Leucocytes ×109/L 9.73 (3.07) 8.02 (2.54) p = 0.01
Platelets ×109/L 233.3 (70.69) 227 (66) p = 0.70
Urea mmol/l 7.61 (4.32) 6.45 (2.17) p = 0.11
Creatinine μmol/l 111.5 (32.18) 86.93 (20.85) p = 0.18
eGFR
n/%b60 ml/min 15/30% 5/16%
n/%b30 ml/min 3/6% 0
Total cholesterol mmol/l median (IQR) 4.7 (3.8, 5.5) 3.8 (3.00, 4.6) p = 0.08
Glucose mmol/l 6.76 (2.33) 6.52 (1.71) p = 0.67
Triglycerides mmol/l median (IQR) 1.38 (1.04, 1.97) 1.35 (0.98, 1.924) p = 0.752
LDL mmol/l median (IQR) 2.6 (1.95, 3.40) 2.05 (1.23, 3.00) p = 0.07
HDL mmol/l median (IQR) 1.1 (0.82, 1.30) 1.1 (0.925, 1.38) p = 0.47
BMI 28.1 (5.52) 28.88 (5.93) p = 0.58
Coronary angiogram 40 6
Beta blockers 18 16 p = 0.25
Asprin 18 16 p = 0.055
Other antiplatelet 12 14 p = 0.25
ACEi/ARB 22 20 p = 0.1
Statin 28 17 p = 1.0
38 K.W. Morrice et al. / IJC Metabolic & Endocrine 5 (2014) 36–41independent clinical team. The ACS group was further subdivided into
ST elevation, non-ST elevation and unstable angina groups (Fig. 1).
4.1. Baseline characteristics
The baseline characteristics are summarized in Table 1. The mean
age of the ACS group was older (66.72 vs 60.26 years, p = 0.048) than
the non-cardiac chest pain (NCCP) group. Both groups had a preponder-
ance ofmaleswith similar incidences of risk factors except for hyperten-
sion. This was found more often in non-cardiac chest pain group 65% vs
40%, p = 0.032.
Electrocardiogram (ECG) analysis showed that 77% of the NCCP
group had a normal ECG or non-speciﬁc changes, compared to only
20% of the ACS group. Of the ACS group 28% (n= 15) had ST elevation.
Of these 15, 10 received thrombolysis, 2 received primary PCI, 2 had
transient elevation, which resolved with medical therapy and 1 had a
previous sub-arachnoid haemorrhage and was treated conservatively.
4.1.1. Intermedin (IMD) levels
Within the ACS group, 6 time periods were established indicating
the time from symptom onset to ﬁrst sampling and to subsequent
samples. The NCCP group only had samples taken up to 16 h afterTable 2
Intermedin levels in both groups.
Mean intermedin levels (pg/ml) and standard deviations of the ACS and non-cardiac chest pai
b8 h 8 h–b16 h 16 h–
ACS
n=
20 25 8
Mean pg/ml ± SD 6.14 ± 2.17 5.87 ± 2.34 4.12
NCCP
n=
20 25
Mean pg/ml ± SD 4.84 ± 2.01 4.88 ± 1.70pain onset. Themean intermedin levels are shown in Table 2 and picto-
rially for ACS in Fig. 2.
The levels of intermedin were non-signiﬁcantly elevated in the ACS
group (6.14 pg/ml ± 2.17) versus the non-cardiac chest pain group
(4.84 pg/ml ± 2.01) level b8 h after chest pain (p = 0.057). At the 8–
16 hour time period the ACS mean of 5.87 ± 2.34 was not signiﬁcantly
different from the non-cardiac chest pain group 4.88 pg/ml ± 1.70,
p = 0.098.
For those samples at exactly 12 h after pain, mean intermedin levels
5.90 pg/mlwere statistically no different from themean level 4.81 pg/ml
in the non-cardiac chest pain group, p = 0.21.
Looking at the presenting sample, the sensitivity for intermedin
detecting ACS was 68%, speciﬁcity 63% with an area under the ROC
curve of 0.341.
Within the ACS group 10 patients had no elevation of troponin on
their presenting sample but it was subsequently raised at 12 h. In this
subgroup the presenting intermedin level of 6.67 pg/ml± 2.32was sig-
niﬁcantly different from the non-cardiac chest pain mean 4.84 pg/ml ±
2.01, p = 0.03 (mean time of sample was 308 min for ACS and 341 for
non-cardiac chest pain).
Similarly STEMI patients had a high presenting (b11 h) intermedin
mean level of 7.03 pg/ml ± 1.60 which was signiﬁcantly differentn group (NCCP) at time points after chest pain onset.
b24 h 24 h–b36 h 36 h–b48 h N48 h
22 15 18
± 1.53 6.21 ± 2.18 4.28 ± 0.97 4.28 ± 2.16
Fig. 2. Mean intermedin levels (pg/ml) with 95% conﬁdence intervals at selected time
points in the ACS patients.
Fig. 3.Mean CGRP levels (pg/ml) with 95% conﬁdence intervals at selected time points in
the ACS patients.
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p = 0.02.
4.1.2. Calcitonin gene-related peptide (CGRP)
Samples were measured in 80 patients, 49 in the ACS group and 31
in the non-cardiac chest pain group (there was not enough serum
collected from one patient to allow CGRP analysis). The results are
shown in Table 3 and pictorially in Fig. 3.
The CGRP level at 8–b16 h in the ACS group was signiﬁcantly differ-
ent from the non-cardiac chest pain group, 8.67 pg/ml ± 2.71 vs
7.08 pg/ml ± 2.36, p= 0.036. However there was no signiﬁcant differ-
ence between the ACS and non-cardiac chest pain groups before 8 h.
The sensitivity of CGRP on a presenting sample of predictingACSwas
61%, speciﬁcity 60% and area under ROC curve 0.32.
In the 10 patients who had an initially negative troponin, but
subsequent elevation at 12 h, the ACS group had a mean value of
8.87 pg/ml ± 2.66 which compared non-signiﬁcantly to the non-
cardiac chest pain group prior to 12 h of 7.03 pg/ml ± 2.92, p =
0.093. At 12 h the mean CGRP level in the ACS group was 9.76 ± 2.58
which was signiﬁcantly different from the 12-hour non-cardiac chest
pain value of 6.64 pg/ml ± 2.05, p = 0.001.
Surprisingly in STEMI patients, where 8 patients had samples prior
to 12h, theirmeanCGRP levelwas 9.43 pg/ml± 2.71,whichwasn't sig-
niﬁcantly different from the non-cardiac chest pain group.
4.1.3. High sensitivity troponin T (HsTnT)
The same group of patients subsequently had high sensitivity
troponin T measured. This was done after completion of the study and
had no bearing on the clinical management of the patient. Results
were available in 77 patients, 49 in the ACS cohort and 28 in the non-
cardiac chest pain group, Table 4.
Comparison of the ACS HsTnT mean 414.9 ng/ml ± 561 with the
control mean 17.22 ng/ml ± 10.4 shows they are signiﬁcantly different
with a p value of 0.006. Comparison at the time point 8 h to 16 h is also
signiﬁcant, p = 0.02.
Of the 30patients in the non-cardiac chest pain group, 8 patients had
a HsTnT N14 ng/l on admission (the 99th percentile value). Of these 7
stayedwithin the biological variation [9] or fell in value. The intermedin
and CGRP values for this group were not signiﬁcantly elevated.Table 3
CGRP levels in both groups.
Mean CGRP levels (pg/ml) and standard deviations of the ACS and NCCP groups at time points
CGRP b8 h 8 h–b16 h 16 h–
ACS
n=
19 23 7
Mean pg/ml ± SD 7.81 ± 2.99 8.67 ± 2.71 6.55
NCCP
n=
20 25
Mean pg/ml ± SD 7.09 ± 3.12 7.08 ± 2.36In 1 patient who presented at 500 min, the HsTnT was 14.6 ng/l
which increased to 45.4 ng/l at 12 h. The standard troponin remained
b0.03 ng/ml at both time points.
5. Discussion
ACS patients are initially differentiated by the ECG, which will mark
out those patients with a STEMI (ST elevation myocardial infarction)
group. This is a declining proportion of ACS patients. The remainder
are subdivided into those that have had myocardial damage from
those that have not. The current gold standard biomarker diagnosing
this myocardial damage is the cardiac troponin, namely the high sensi-
tivity troponins [20]. The highly sensitive troponin has a N95% negative
predictive value on a ﬁrst presentation sample [7,21]. However the
improved analytical ability of the assay has revealed a chronic elevation
in a cohort of patients who don't have acute coronary syndrome. There-
fore similar to the contemporary troponin, again, a repeat sample
is required 3–6 h after presentation to rule out a signiﬁcant change
[22,23]. Another marker with the troponin could ﬁll this void.
This study provides theﬁrst humandata on the biologically plausible
biomarker intermedin (IMD). It shows intermedin is detectable, at low
levels, in both normal control patients and patients with acute coronary
syndrome; it appears to be at its highest elevation on presentation and
again at 24 h, with a trend towards elevation in ACS patients.
In those ACS patientswho are initially troponin T negative, themean
intermedin level was 6.65 pg/ml and was signiﬁcantly different from
the control value (4.84 pg/ml) at this early time period, b8 h. However,
the sensitivity and speciﬁcity for a presenting sample are disappointing,
68% and 63% respectively, which is not better than the high sensitivity
troponins.
In this cohort the increase from a normal control value to a diseased
value is only an increase of 25–30%. This is a small increase when you
consider a troponin can increase several hundred times. Estimating a
normal distribution using the summary statistics in our study leads to
an ACS curve, which overlaps with the upper values of ‘normal’ in theafter chest pain onset.
b24 h 24 h–b36 h 36 h–b48 h N48 h
24 15 19
± 1.57 7.89 ± 2.73 7.58 ± 2.00 8.19 ± 2.86
Table 4
High sensitivity troponin levels in both groups.
Mean HsTnT values (ng/ml) and standard deviations in the ACS and NCCP groups at time points after chest pain onset.
HsTnT b8 h 8 h–b16 h 16 h–b24 h 24 h–b36 h 36 h–b48 h N48 h
ACS
n=
19 24 8 23 13 19
Mean ng/l ± sd 414 ± 561 3325 ± 6497 1743 ± 2121 2010 ± 3492 1503 ± 1553 1525 ± 1687
NCCP
n=
18 20
Mean ng/l ± sd 17.22 ± 10.4 21.54 ± 12.4
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speciﬁcity andROCvalues obtained. It is therefore likely that intermedin
may not be particularly helpful in discriminating ACS patients from the
chest pain population.
With the limited exploration of intermedin, confounders are
unknown, but some studies suggest that hypertension [24] or renal
dysfunction [25] may inﬂuence levels.5.1. CGRP
In our study CGRPwasmeasureable peripherally in all patients, both
ACS patients and controls. The CGRP levels were higher than those
found for intermedin. The mean level of CGRP at the earliest time
point, was 7.09 pg/ml in the control patients and 7.81 pg/ml in the
ACS patients. In the previous studies of CGRP, a ‘normal’ value has
shown a lot of variation from 1.86 pg/ml [26], 3.86 pg/ml [27] to
18.2 pg/ml in treated hypertensive patients [28]. One analysis in
young normal people found mean values of 42.8 ± 7.12 pg/ml [29].
This may be the affect of different assays and antibody characteristics.
The ACS patients again showed a trend to a higher elevation at the
earliest time point, and this was statistically signiﬁcant at 12 h after
chest pain onset, p = 0.005. The time course of CGRP appears to peak
at 8 to 16 h after pain, before falling back to a plateau level, which is
still higher than control values.
However as with intermedin the sensitivity and speciﬁcity at just
over 60% are not rigorous enough to be useful as a discriminating test
for ACS.
A possible confounder is the use of nitroglycerin or long acting
nitrate. CGRP and nitric oxide (NO) appear to be interlinked, where
treatment with nitroglycerin causes a decrease in blood pressure and
an increase in CGRP levels [30]. High levels of CGRP cause an increase
in endogenous NO levels. When the nerve stores are depleted, such as
with capsaicin, or CGRP antagonist, then the effect of nitroglycerin is
signiﬁcantly impaired [31]. This could impact our results, where
patients have received GTN spray prior to blood sampling, which
could raise CGRP levels, when not actually in the setting of ACS. This
may be an explanation for the high levels seen on presentation in a
few of the control samples. However, even with these high levels in
the controls, there was still a signiﬁcant difference in means at the
12 hour time point. The ACS group would have been as likely to receive
nitroglycerin as a treatment therapy on presentation.
In those patients who present with a negative troponin, CGRP was
not signiﬁcantly raised in comparison to controls until we reached the
12-hour time period. Therefore unlike intermedin, CGRP appears to be
elevated later. This is surprising, given that CGRP is stored and released
from the nerves on pain initiation. Intermedin needs to be cleaved and
manufactured, which you would expect to take longer than the process
of simple release from vesicle stores. One possible explanation for this is
the use of peripheral sampling. Kallner in his assessment of CGRP post
CABG ischaemia, found levels signiﬁcantly elevated in coronary sinus
blood, but not raised from peripheral venous sampling [18]. The animal
studies havemainly used central sampling, hence itmay take prolonged
ischaemia/infarction for CGRP levels to become exceedingly elevated
that they can be detected peripherally.5.2. Troponin
Out of 50 ACS patients, the contemporary troponin was elevated in
37, on a presenting sample. In comparison the high sensitivity was
elevated in 48 out of 49 patients on their presenting sample. Only 1
patient had a value less than the 99th percentile cut-off, which was a
sample taken before 4 h after chest pain onset.
It would have re-classiﬁed one of the non-cardiac chest pain and 1 of
the unstable anginas to a NSTEMI.
The spread of results show why HsTnT is a better marker. It has
extremely low values in control patients, b14 ng/l and increases to
exceedingly high levels in positive cases. The percentage increase from
a ‘normal’ value to a ‘diseased’ value is many hundredfold, making
differentiating diseased from a high normal much easier to do.
6. Limitations
There are several limitations within the study, the ﬁrst is the small
numbers of patients within the study. The groups are small and num-
bers at some of the time points are limited, which means we have to
be guarded in our overall conclusions.
We know some of the interactions of CGRP in hypertension, conges-
tive cardiac failure and possibly how intermedin's levels are affected in
these conditions. But overall a full understanding of what happens to
these molecules in humans in various conditions is not established.
CGRP's full interaction with nitrates and how one affects the other,
needs to be elucidated further as nitrates are amainstay of angina therapy
and a ﬁrst line therapy in myocardial infarction.
These peptides may have more local effects than systemic effects
and they may not be released in great enough quantities to be detected
systemically/peripherally.
Currently themethod of detecting CGRP and intermedin is by use of
a 3 day radio-immunoassay,which is acceptable for a research basis, but
not if you wish to decide urgent patient management. An ELISA assay
has been made by Phoenix Pharmaceuticals for intermedin, but it's
sensitivity is much less than the radioimmunoassay kit, with a lower
reading of 100 pg/ml. This level is far in excess of the values we were
obtaining. Similarly with CGRP, the lower level of detection in the
ELISA kit is 280 pg/ml.
Finally, this was a proof of concept study and didn't look at long-
term morbidity and mortality, hence the prognostic implications of
raised levels are uncertain.
7. Conclusions
This is the ﬁrst in man study of the cardioprotective peptide inter-
medin, it does appear to have a small rise in acute coronary syndrome,
but the magnitude (25–30%) of this may make its clinical applicability
limited. Its clinical confounders remain uncertain.
CGRP also rises in ACS, later than intermedin, but the release appears
to bemore sustained. CGRP has a lot of local in-vitro effects thatmay not
translate to a measurable systemic/peripheral level.
TheHsTnT is a bettermarker of ACS than both experimentalmarkers
at all time points.
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Appendix A
Intermedin primary antibody reactivityCross reactivity Peptide % cross-reactivityIntermedin/AM-2 (human) 100
Intermedin/AM-2 (rat) 100
Intermedin/AM-2 (mouse) 100
Intermedin-53 (human) 100
Intermedin/AM-2 (8–47) (human) 100
Adrenomedullin/AM-1/ADM-1 (human) 0
Adrenomedullin/AM-1/ADM-1 (rat) 0
Prepro-intermedin (25–56) (human) 0
Prepro-intermedin (57–92) (human) 0
CGRP (human)
CGRP (rat) 0
0Sequence Thr-Gln-Ala-Gln-Leu-Leu-Arg-Val-Gly-Cys-Val-Leu-Gly-Thr-Cys-Gln-
Val-Gln-Asn-Leu-Ser-His-Arg-Leu-Trp-Gln-Leu-Met-Gly-Pro-Ala-Gly-
Arg-Gln-Asp-Ser-Ala-Pro-Val-Asp-Pro-Ser-Ser-Pro-His-Ser-Tyr-NH2
Disulphide bridge between: Cys10 & Cys15Calcitonin gene-related peptide reactivity.Cross reactivity Peptide % cross-reactivityCGRP (human) 100
CGRP (8–37) (human) 100
Amylin (human) 0
Amylin amide (human) 0
ADM (human) 0
Amylin (rat) 0
Calcitonin (salmon) 0
CRSP (24–38) Cys0 (porcine) 0
CRSP (porcine) 0
Substance P 0Sequence Ala-Cys-Asp-Thr-Ala-Thr-Cys-Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-
Ser-Arg-Ser-Gly-Gly-Val-Val-Lys-Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-
Gly-Ser-Lys-Ala-Phe-NH2
Disulphide bridge between: Cys2 & Cys7References
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